ASCO 2021 – Martin Reck

Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.

Here is the full ASCO 2021 report.

More posts

Load More Posts